Epithelial-mesenchymal transition in malignant mesothelioma

Modern Pathology

Volumn 25, Issue 1, 2012, Pages 86-99

  Fassina, Ambrogio ^a   Cappellesso, Rocco ^a   Guzzardo, Vincenza ^a   Dalla Via, Lisa ^a   Piccolo, Stefano ^a   Ventura, Laura ^a   Fassan, Matteo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

epithelial mesenchymal transition; malignant mesothelioma; miR 205; ZEB1; ZEB2

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BETA CATENIN; CALVASCULIN; CYTOKERATIN 5; CYTOKERATIN 6; GELATINASE A; GELATINASE B; NERVE CELL ADHESION MOLECULE; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; UVOMORULIN; VIMENTIN;

ADULT; AGED; ARTICLE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MALIGNANT MESOTHELIOMA; MESOTHELIUM CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MESOTHELIOMA; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS; PHENOTYPE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TIME FACTORS; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84855357590     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.144     Document Type: Article

References (43)

1. Thiery JP, Acloque H, Huang RY, et al. Epithelialmesenchymal transitions in development and disease. Cell 2009;139:871-890.
2. Kalluri R, Weinberg RA. The basics of epithelialmesenchymal transition. J Clin Invest 2009;119: 1420-1428.
3. Acloque H, Adams MS, Fishwick K, et al. Epithelialmesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest 2009;119:1438-1449.
4. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008;14:818-829. (Pubitemid 351757205)
5. Voulgari A, Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 2009;1796:75-90.
6. Mani SA, Guo W, Liao MJ, et al. The epithelialmesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-715. (Pubitemid 351636299)
7. Zeisberg M, Neilson EG. Biomarkers for epithelialmesenchymal transitions. J Clin Invest 2009;119: 1429-1437.
8. Nieto MA. The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol 2002;3:155-166.
9. Hajra KM, Chen DY, Fearon ER. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res 2002;62:1613-1618. (Pubitemid 34408479)
10. Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004;117:927-939. (Pubitemid 38798858)
11. Van de Walle C, Van Roy F, Berx G. The role of the ZEB family of transcription factors in development and disease. Cell Mol Life Sci 2009;66:773-787.
12. Brabletz S, Brabletz T. The ZEB/miR-200 feedback loop-a motor of cellular plasticity in development and cancer? EMBO Rep 2010;11:670-677.
13. Cano A, Perez-Moreno MA, Rodrigo I, et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000;2:76-83.
14. Eger A, Aigner K, Sonderegger S, et al. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 2005;24:2375-2385. (Pubitemid 40546696)
15. Sanchez-Tillo E, Lazaro A, Torrent R, et al. ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1. Oncogene 2010;29:3490-3500.
16. Casas E, Kim J, Bendesky A, et al. Snail2 is an essential mediator of twist1-induced epithelial mesenchymal transition and metastasis. Cancer Res 2011;71:245-254.
17. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-297.
18. Fassina A, Cappellesso R, Fassan M. Classification of non-small cell lung carcinoma in trans-thoracic needle specimens using microRNA expression profiling. Chest 2011; doi:10.1378/CHEST.11-0708 (in press).
19. Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008;10:593-601. (Pubitemid 351627379)
20. Gregory PA, Bracken CP, Bert AG, et al. MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle 2008;7:3112-3118.
21. Korpal M, Lee ES, Hu G, et al. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008;283:14910-14914.
22. Bracken CP, Gregory PA, Kolesnikoff N, et al. A doublenegative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res 2008;68:7846-7854.
23. Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol 2010;11:252-263.
24. Travis WD, Brambilla E, Muller-Hermelink H, et al. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC Press: Lyon, 2004, pp 125-144.
25. Schramm A, Opitz I, Thies S, et al. Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma. Eur J Cardiothorac Surg 2010;37:566-572.
26. Rusch VW, Venkatraman ES. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg 1999;68:1799-1804.
27. Zellos LS, Sugarbaker DJ. Multimodality treatment of diffuse malignant pleural mesothelioma. Semin Oncol 2002;29:41-50. (Pubitemid 34163534)
28. Milano MT, Zhang H. Malignant pleural mesothelioma: a population-based study of survival. J Thorac Oncol 2010;5:1841-1848.
29. Kadota K, Suzuki K, Sima CS, et al. Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma. J Thorac Oncol 2011;6:896-904.
30. Albertin G, Guidolin D, Sorato E, et al. Pro-angiogenic activity of Urotensin-II on different human vascular endothelial cell populations. Regul Pept 2009;157:64-71.
31. Fassan M, Volinia S, Palatini J, et al. MicroRNA expression profiling in human Barrett's carcinogenesis. Int J Cancer 2011;129:1661-1670.
32. Fassan M, Baffa R, Palazzo JP, et al. MicroRNA expression profiling of male breast cancer. Breast Cancer Res 2009;11:R58.
33. Baffa R, Fassan M, Volinia S, et al. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol 2009;219:214-221.
34. Monami G, Gonzalez EM, Hellman M, et al. Proepithelin promotes migration and invasion of 5637 bladder cancer cells through the activation of ERK1/2 and the formation of a paxillin/FAK/ERK complex. Cancer Res 2006;66:7103-7110. (Pubitemid 44197687)
35. Lovat F, Bitto A, Xu SQ, et al. Proepithelin is an autocrine growth factor for bladder cancer. Carcinogenesis 2009;30:861-868.
36. Mandal M, Myers JN, Lippman SM, et al. Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features. Cancer 2008;112:2088-2100. (Pubitemid 351574086)
37. Nguyen PT, Kudo Y, Yoshida M, et al. N-cadherin expression is correlated with metastasis of spindle cell carcinoma of head and neck region. J Oral Pathol Med 2011;40:77-82.
38. Schwock J, Bradley G, Ho JC, et al. SNAI1 expression and the mesenchymal phenotype: an immunohistochemical study performed on 46 cases of oral squamous cell carcinoma. BMC Clin Pathol 2010;10:1.
39. Cates JM, Dupont WD, Barnes JW, et al. Markers of epithelial-mesenchymal transition and epithelial differentiation in sarcomatoid carcinoma: utility in the differential diagnosis with sarcoma. Appl Immunohistochem Mol Morphol 2008;16:251-262. (Pubitemid 351589558)
40. Tarin D, Thompson EW, Newgreen DF. The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res 2005;65:5996-6000. (Pubitemid 40994379)
41. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 2006;66:8319-8326. (Pubitemid 44449137)
42. Scheel C, Onder T, Karnoub A, et al. Adaptation versus selection: the origins of metastatic behavior. Cancer Res 2007;67:11476-11479; discussion 11479-11480.
43. Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-925. (Pubitemid 37493640)